Four Decades for Justice
February 16, 2017
On February 15, 2017, Johnson & Johnson received a binding offer from Integra LifeSciences Holdings Corporation to acquire its Codman Neurosurgery business for $1.045 billion in cash. Codman Neurosurgery offers a portfolio of devices focused on advanced hydrocephalus, neuro‑critical care and operative neurosurgery. If the binding offer is accepted, upon closing, Integra will be a leading global provider of neurosurgical products. Cravath is representing Johnson & Johnson in connection with the transaction.
The Cravath team is led by partner Robert I. Townsend III and includes associates Cameron S. Stanton, Vince A. Ferrito and Megan E. Fitzgerald on M&A matters; partner Craig F. Arcella on financing matters; partner J. Leonard Teti II and associates Sara L. Lykken and Lingfeng Li on tax matters; partner Jonathan J. Katz and associates Matthew J. Bobby and Peretz Riesenberg on executive compensation and benefits matters; partner Matthew Morreale on environmental matters; and associate Jason M. Sandler on intellectual property matters.
Deals & Cases
November 01, 2022
On November 1, 2022, Johnson & Johnson and Abiomed, a leader in breakthrough heart, lung and kidney support technologies, announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35 per share in cash if certain commercial and clinical milestones are achieved. Cravath is representing Johnson & Johnson in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.